Peter J Houghton Selected Research

Temozolomide (Temodar)

2/2022	PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma.
2/2015	Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
5/2013	Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
2/2006	Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
2/2004	Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
5/2003	The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
9/2002	O6-benzylguanine-mediated enhancement of chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter J Houghton Research Topics

Disease

175	Neoplasms (Cancer) 11/2023 - 07/2002
35	Rhabdomyosarcoma 01/2023 - 04/2002
30	Ewing Sarcoma (Sarcoma, Ewing) 10/2023 - 08/2007
26	Neuroblastoma 01/2020 - 09/2002
24	Sarcoma (Soft Tissue Sarcoma) 01/2023 - 04/2008
24	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 02/2006
21	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 10/2005
20	Leukemia 11/2023 - 08/2007
11	Wilms Tumor (Wilm's Tumor) 01/2021 - 12/2003
10	Hypoxia (Hypoxemia) 01/2022 - 12/2004
10	Brain Neoplasms (Brain Tumor) 01/2022 - 09/2002
9	Rhabdoid Tumor (Rhabdoid Tumors) 01/2021 - 05/2008
7	Glioblastoma (Glioblastoma Multiforme) 10/2015 - 06/2008
7	Alzheimer Disease (Alzheimer's Disease) 01/2012 - 03/2004
6	Glioma (Gliomas) 01/2022 - 07/2002
6	Alveolar Rhabdomyosarcoma 01/2019 - 03/2008
5	Medulloblastoma 02/2015 - 08/2004
5	Breast Neoplasms (Breast Cancer) 10/2009 - 12/2003
4	Colonic Neoplasms (Colon Cancer) 01/2021 - 08/2009
4	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2006
4	Cognitive Dysfunction 01/2016 - 01/2003
4	Astrocytoma (Pilocytic Astrocytoma) 10/2015 - 01/2006
4	Diarrhea 08/2012 - 07/2002
3	Tuberous Sclerosis (Bourneville's Disease) 01/2022 - 02/2008
3	Thrombocytopenia (Thrombopenia) 12/2019 - 04/2015
3	Genetic Translocation (Chromosomal Translocation) 11/2017 - 11/2014
3	Lymphoma (Lymphomas) 07/2013 - 03/2006
3	Disease Progression 01/2012 - 06/2005
3	Carcinoma (Carcinomatosis) 06/2008 - 04/2002
2	Drug-Related Side Effects and Adverse Reactions 12/2019 - 08/2009
2	Embryonal Rhabdomyosarcoma 01/2019 - 07/2007

Drug/Important Bio-Agent (IBA)

45	N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA 01/2021 - 12/2007
18	Proteins (Proteins, Gene)FDA Link 01/2024 - 12/2003
18	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 07/2002
17	Sirolimus (Rapamycin)FDA Link 01/2022 - 04/2002
13	Mechanistic Target of Rapamycin Complex 1IBA 01/2022 - 02/2008
10	DNA (Deoxyribonucleic Acid)IBA 11/2023 - 09/2002
10	Cytotoxins (Cytolysins)IBA 12/2021 - 08/2007
10	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 08/2007
9	Biomarkers (Surrogate Marker)IBA 01/2023 - 03/2010
9	TOR Serine-Threonine KinasesIBA 01/2018 - 04/2002
9	Topotecan (Hycamtin)FDA LinkGeneric 11/2013 - 02/2003
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 05/2007
7	RNA (Ribonucleic Acid)IBA 11/2023 - 10/2014
7	Temozolomide (Temodar)FDA LinkGeneric 02/2022 - 09/2002
7	LigandsIBA 11/2020 - 10/2009
7	Phosphotransferases (Kinase)IBA 01/2020 - 02/2008
6	ProdrugsIBA 01/2021 - 09/2002
6	Cisplatin (Platino)FDA LinkGeneric 02/2018 - 05/2008
6	EnzymesIBA 02/2018 - 07/2002
5	AntibodiesIBA 01/2023 - 03/2012
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 12/2013
5	Messenger RNA (mRNA)IBA 01/2022 - 02/2012
5	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 04/2013
5	EWS-FLI fusion proteinIBA 01/2021 - 03/2008
5	CamptothecinIBA 01/2020 - 12/2003
5	Antineoplastic Agents (Antineoplastics)IBA 12/2019 - 05/2003
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 09/2002
4	Somatomedin Receptors (Somatomedin Receptor)IBA 01/2023 - 10/2009
4	Insulin-Like PeptidesIBA 01/2023 - 06/2008
4	talazoparibIBA 02/2022 - 01/2015
4	Insulin-Like Growth Factor II (Somatomedin A)IBA 01/2022 - 03/2012
4	Small Interfering RNA (siRNA)IBA 01/2020 - 09/2008
4	navitoclaxIBA 12/2019 - 06/2008
4	Histone Deacetylase InhibitorsIBA 01/2019 - 01/2006
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2016 - 12/2004
4	cixutumumabIBA 12/2015 - 07/2010
4	temsirolimus FDA Link 04/2015 - 08/2003
4	Insulin-Like Growth Factor I (IGF-1)IBA 06/2013 - 01/2003
4	Cholinergic Agents (Cholinergics)IBA 10/2008 - 01/2003
4	Eukaryotic Initiation Factor-4EIBA 09/2008 - 04/2002
3	Membrane Proteins (Integral Membrane Proteins)IBA 10/2023 - 09/2021
3	CytokinesIBA 01/2023 - 01/2012
3	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 08/2009
3	MLN 8237IBA 01/2019 - 07/2010
3	Transcription Factors (Transcription Factor)IBA 11/2017 - 01/2014
3	(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA 06/2017 - 02/2012
3	Taxoids (Taxanes)IBA 11/2015 - 10/2005
3	Antimitotic AgentsIBA 07/2015 - 10/2005
3	Angiogenesis InhibitorsIBA 11/2014 - 09/2012
3	Insulin (Novolin)FDA Link 06/2013 - 06/2006
3	Gefitinib (Iressa)FDA Link 08/2012 - 10/2004
3	FlavonoidsIBA 01/2012 - 03/2007
3	Phosphatidylinositols (Phosphatidylinositol)IBA 08/2011 - 01/2003
3	Type I DNA Topoisomerases (Topoisomerase I)IBA 05/2010 - 09/2002
3	Everolimus FDA Link 03/2010 - 08/2003
3	Acetylcholine (Acetylcholine Chloride)FDA Link 04/2007 - 11/2004
3	AcetylcholinesteraseIBA 04/2007 - 03/2004
2	Peptides (Polypeptides)IBA 01/2023 - 02/2015
2	Alkylating AgentsIBA 02/2022 - 09/2008
2	trametinibIBA 01/2022 - 01/2022
2	Histones (Histone)IBA 11/2021 - 01/2006
2	ChromatinIBA 01/2021 - 01/2018
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 02/2015
2	tazemetostatIBA 01/2021 - 01/2017
2	eribulin FDA Link 01/2020 - 08/2013
2	ErbB Receptors (EGF Receptor)IBA 02/2018 - 09/2009

Therapy/Procedure

46	Therapeutics 01/2023 - 07/2002
11	Drug Therapy (Chemotherapy) 11/2021 - 09/2002
8	Radiotherapy 11/2021 - 02/2006